xCELLigence RTCA eSight - ??? ? ????
??? ??? ?? ? ???? ??? ??? RTCA eSight ?????? ??? ?? ?? ????, ?? FDA 21 CFR Part 11 ?? ??? ?????.
- RTCA ???
見積依頼
?? ??
- ??? ???? ?? xCELLigence ??? ?? ?? ??? 5?, 10?, 20?? ????? ?? ???, ?? ? ???? ??? ???? ???? ?? ?? ? ??? ?? ???? ????.
- ?? well ??? ??: QC? ????? ?? ??? ????? ????? ? ?? well? ???
- ?? ????? ??? ??? well?? ?? ????? ???? ??? ???? ??? ??? ???
- ??? ?? ????? ???? ?? ??, ?? ? ??? ?????? ??? ????? ?? 2D ?? 3D ?? ?? ??? ???? ?????? ??? ?? ??? ??
- ??? ????????(6-, 12-, 24-, 48-, 96- ?? 384-well)? ?? ??(35mm ?? 60mm ??)? ?? ?? ??? ??? ??? ??? ??? 3?? ?? ??, ??? ??? ?? ??? ??
- ?? ?, ??, ?? ??/??, ?? ?? ? ?? ?? ?? ??? ?? ??? ??
- 5?? 96-well ?? ????????(??? 5? ??) ???? ??? ???? ??, 3D ????? ?? ??, ???? ?? ??? ??? ??? ?? 21 CFR Part 11 ?? ?? ??
- ?? ????
-
- ?? ??
- ?? ???
- ????
- ???
- ??
- ?? ??
- Frequently Asked Questions
-
- ??? ???
- ?? ??
- ?? ?? ?????
??? ??? ?? ?????? ???? ?? ?? ?????.
Seahorse ??? ?? ?? ?? ?? ???
Dr. Zelia Geouveia
Institut Curie
We are a laboratory working in cancer research, namely chimeric antigen receptor (CAR)-T cells targeting different antigens in the tumor. We were seeking a high throughput platform that would allow us to evaluate CAR-T cells killing in real-time. We were also interested in visualizing the killing in real time. The xCELLigence RTCA eSight was one of the technologies that could provide such information using impedance and live cell imaging (one machine, two different and precious information). When compared with other instruments that could provide imaging information only, the image quality was similar but we would not have the impedance for comparison. Thus, we decided that having both
? ??? ?????
In Vivo DNA-launched Bispecific T Cell Engager Targeting IL-13Ra2 Controls Tumor Growth in an Animal Model of Glioblastoma Multiforme
Immuno-oncology research is changing the landscape of cancer treatment by harnessing the immune system to attack cancer cells. These immunotherapies utilize both the adaptive and innate arms of the immune system, playing a pivotal role in a host’s defense against tumors. Join the Agilent Immuno-Oncology webinar series and learn how experts in the field are making groundbreaking discoveries and taking steps towards a cancer-free world. Glioblastoma is an aggressive tumor with poor survival rates. Bispecific T cell engagers (BTEs) against different cancers are in various stages of clinical development. Toxicity resulting from cytokine release syndrome and the short half-life of BTEs, which necessitates continuous infusion—complicating delivery and increasing costs—are major challenges in the field. Here we describe the development of in vivo DNA-launched BTEs (dBTEs) with highly focused targeting of interleukin-13 receptor a2 (IL-13Ra2), a glioblastoma cell-surface target. We developed 4 BTEs targeting 2 epitopes of IL-13Ra2 and studied how heavy-light chain orientation affects BTE function. The dBTEs induced T cell activation, cytokine production, and tumor cytolysis in the presence of IL-13Ra2+ tumor cells, but we observed unique patterns of immune activation. We found a strong correlation between granzyme B secretion and dBTE-induced cytolysis of specific and nonspecific tumors. We down-selected dBTE PB01-forward based on lower cytokine induction profile and highest activation specificity. In vivo, dBTE PB01-forward demonstrated an improved half-life versus intravenous recombinant BTE delivery. In an orthotopic glioblastoma model, dBTE PB01-forward controlled tumor growth, improving animal survival, supporting the hypothesis that the blood-brain barrier does not affect the function of systemically delivered dBTE. Further study of PB01-forward for targeting glioblastoma and other IL-13Ra2+ cancers is warranted.
Using Impedance in Microbiology: Applications in Biofilm Research, Discovery of Novel Antimicrobials, and Selection of Antibiotic Treatments
Regulatory agencies set thresholds for volatile organic compounds (VOCs). Learn about GC/MS with purge & trap for VOC analysis to requirements of EPA 8260 & EPA 524.2.
Armor CAR T Cells with Enhanced Potency for Cancer Immunotherapy
Explore rapid generation of non-activated CAR T cells with enhanced potency for cancer immunotherapy in this on-demand webinar from Agilent.
Agilent xCELLigence RTCA ???? ?? FDA ??? ??? ?? ?? ??? ??? ?????
Agilent xCELLigence ??? ?? ??(RTCA) ??? Autolus Therapeutics?? ?? ??? CAR T ??? AUCATZYL? ???? ??? ???? ?????. xCELLigence RTCA ??? ?? ???? ??? ??? ??????. ????? ???? ??? ? ?? ?? ?? ??? ?????? ??? ???? ????? Autolus? ??? ??????.
- 15 Jul 2025